<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83403">
  <stage>Registered</stage>
  <submitdate>27/11/2008</submitdate>
  <approvaldate>23/05/2014</approvaldate>
  <actrnumber>ACTRN12614000554662</actrnumber>
  <trial_identification>
    <studytitle>A Prospective Study of the Effects of Pregabalin versus Placebo  on the incidence and intensity of pain after video-assisted thoracoscopic surgery.</studytitle>
    <scientifictitle>A Prospective Study of the Effects of Pregabalin versus Placebo  on the incidence and intensity of pain after thoracoscopic surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>post thoracotomy pain syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>prevention of long term pain following thorocotomy operation. Intervention involves using 300mg oral pregabalin administered prior to commencement of thoracoscopic surgery (day 1) and continued for a further 5 postoperative days (day 6). Both preoperative pregabalin and postoperative pregabalin are compared with oral placebo. Blinded nursing staff in hospital administering pregabalin/placebo will sign medication chart to confirm that the pregabalin/placebo has been taken by the participant. </interventions>
    <comparator>Control treatment is oral placebo, taken twice daily for 6 days. Placebo is a salt tablet</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Average Visual Analogue Scale (VAS) rating with deep breathing versus time for the period of  0 to 9 months after initial video assisted thoracoscopic surgery (VATS). The VAS will be measured postoperatively, at 6 weeks, , and at 3, 6, and 9 months: these  scores will be summed then divided by 5 to give the average pain intensity score over the  0 to 9 month post-operative period.</outcome>
      <timepoint>from completion of surgery to 9 months after surgery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quantity of opioid use in oral morphine equivalent in milligrams over
i)	the first 5 post-operative days
ii)	from day 6 (after completion of pregabalin) until 9 months. </outcome>
      <timepoint>from commencement of surgery to 9 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Short form McGill questionnaire score change on discharge from hospital and at 9 months after surgery</outcome>
      <timepoint>prior to surgery, day 6 after commencment of pregabalin, 6 weeks after surgery, 3 months after surgery, , 6 months after surgery,  9 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SPF-12 score change at hospital admission and at 9 months after surgery</outcome>
      <timepoint>from immediately prior to surgery until 9 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in spirometric lung function </outcome>
      <timepoint>from prior to surgery, on day 6 after commencement pregabalin/placebo</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of recovery score</outcome>
      <timepoint>before surgery and at 24 hours after surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients having video assisted thoracoscopic surgery (VATS)
Conscious
Able to understand use of "PCA" ( Patient Controlled Analgesia)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Morphine or paracetamol contraindication or allergy
Allergy to pregabalin
History of chronic pain
Evolving myocardial infarction, arrhythmias at time of surgery
Preoperative respiratory function tests showing a forced vital capacity&lt;60% predicted, forced expiratory volume 1s &lt;60%, or both
Renal insufficiency (creatinine &gt;15mg/dL)
Liver dysfunction (aspartate aminotransferase, alanine aminotransferase, or both &gt;40u/L)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients are located via the operating room list or via pre admission clinic prior to their surgery. Allocation of treatment group is random. That is they receive the next kit number containg the trial medications, that is numbered containers</concealment>
    <sequence>Computer generated random randomisation assignments</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/10/2007</anticipatedstartdate>
    <actualstartdate>10/10/2007</actualstartdate>
    <anticipatedenddate>1/03/2013</anticipatedenddate>
    <actualenddate>23/04/2013</actualenddate>
    <samplesize>95</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3004</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Alex Konstantatos</primarysponsorname>
    <primarysponsoraddress>C/o Alfred Hospital, Commercial Rd, Melbourne, Victoria Australia 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Pharmaceuticals Investigator initiated funding</fundingname>
      <fundingaddress>235 East 42nd Street, New York. New York 10017 USA</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Alfred Hospital Research and Ethics Committee</sponsorname>
      <sponsoraddress>Alfred Hosptial.55 Commercial Road, Melbourne, Victoria, Australia, 3004</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study proposes to investigate whether a drug with specific effects which damp excessive nerve mediated activity can prevent the long term occurence of pain after chest surgery.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ALFRED HOSPITAL ETHICS COMMITTEE</ethicname>
      <ethicaddress>55 Commercial Road, Melbourne. Victoria 3004</ethicaddress>
      <ethicapprovaldate>12/07/2007</ethicapprovaldate>
      <hrec>169 / 06</hrec>
      <ethicsubmitdate>11/05/2006</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr. Alex Konstantatos</name>
      <address>Anaesthetic Department. Alfred Hospital, 55 Commercial Road Melbourne. Victoria 3004</address>
      <phone>+61 3 90762854</phone>
      <fax>+61 3 90762813</fax>
      <email>a.konstantatos@alfred.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Ms. Dana Boyd</name>
      <address>Anaesthetic Department. Alfred Hospital, 55 Commercial Road Melbourne. Victoira 3004</address>
      <phone>+61 3 90762648</phone>
      <fax>+61 3 90768076</fax>
      <email>d.boyd@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Ms Dana boyd</name>
      <address>Anaesthetic Department. Alfred Hospital, 55 Commercial Road Melbourne. Victoria 3004</address>
      <phone>+61 3 90762648</phone>
      <fax>+61 3 90768076</fax>
      <email>d.boyd@alfred.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Alex konstantatos</name>
      <address>Alfred Hospital
Commercial Rd Melbourne, Victoria, Australia 3004</address>
      <phone>+61 3 90762000</phone>
      <fax />
      <email>a.konstantatos@alfred.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>